Related Experiment Videos

The Ped-APS Registry: the antiphospholipid syndrome in childhood

T Avcin1, R Cimaz, B Rozman

  • 1Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia. tadej.avcin@kclj.si

Lupus
|August 13, 2009
PubMed

Insights

The Ped-APS Registry collects data on childhood antiphospholipid syndrome (APS). This international effort aims to improve understanding and treatment of APS in children through multicenter studies.

Area of Science:

  • Pediatric Rheumatology
  • Autoimmune Diseases
  • Thrombosis Research

Background:

  • Antiphospholipid syndrome (APS) is increasingly recognized in pediatric autoimmune and non-autoimmune diseases.
  • Studying childhood APS is challenging due to low prevalence and heterogeneity.
  • The European Forum on Antiphospholipid Antibodies and the Juvenile Systemic Lupus Erythematosus Working Group initiated the Ped-APS Registry.

Purpose of the Study:

  • To foster and conduct multicenter, controlled studies on pediatric APS patients.
  • To establish a standardized data collection for children with antiphospholipid antibodies (aPL)-related thrombosis.
  • To facilitate systematic research into childhood APS.

Main Methods:

  • Initiated an international registry for pediatric APS patients (Ped-APS Registry) in 2004.
  • Collaborative project involving European research groups.
  • Standardized collection of clinical, laboratory, and therapeutic data.

Main Results:

  • The registry currently documents data from 133 children with aPL-related thrombosis across 14 countries.
  • Established a standardized dataset for pediatric APS patients.
  • Facilitated international collaboration in childhood APS research.

Conclusions:

  • The Ped-APS Registry is a crucial resource for studying pediatric APS.
  • Future research priorities include prospective enrollment, adult vs. pediatric APS comparison, genetic risk factors, and non-thrombotic manifestations.
  • The registry aims to improve the diagnosis and management of APS in children.

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pedigree Analysis01:35

Pedigree Analysis

Overview